Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape
No se pudo agregar al carrito
Solo puedes tener X títulos en el carrito para realizar el pago.
Add to Cart failed.
Por favor prueba de nuevo más tarde
Error al Agregar a Lista de Deseos.
Por favor prueba de nuevo más tarde
Error al eliminar de la lista de deseos.
Por favor prueba de nuevo más tarde
Error al añadir a tu biblioteca
Por favor intenta de nuevo
Error al seguir el podcast
Intenta nuevamente
Error al dejar de seguir el podcast
Intenta nuevamente
Bispecific Antibodies for PD-1 and VEGF: Impact and Market Dynamics for IO Landscape
-
Narrado por:
-
De:
Acerca de esta escucha
This podcast, recorded at the 2025 Immuno-Oncology 360º (IO360º) Summit, explores the clinical and market implications of emerging data on bispecific antibodies targeting PD-1 and VEGF and their potential to disrupt existing immunotherapy paradigms.
More specifically:
- Assessing the potential of this therapeutic approach to challenge established treatments like pembrolizumab by targeting both PD-1 and VEGF
- Insights into how these developments could influence industry trends and investor sentiment
- Forward-looking forecasts on market share and commercial positioning for PD-1/PD-L1 and VEGF-targeting therapies
In this podcast:
- Roy Baynes, MD, PhD, EVP & CMO at Eikon Therapeutics
- Asthika Goonewardene, MBA, Managing Director, Senior Biotech Analyst at Truist Securities
For more information, go to IO360summit.com
adbl_web_global_use_to_activate_T1_webcro805_stickypopup
Todavía no hay opiniones